Home
Bergonie Institute

Bergonie Institute Market Share Analysis for August 2026

Bienvenue sur le site internet officiel de l'Institut Bergonié, Centre de Lutte Contre le Cancer (CLCC) de la région Nouvelle-Aquitaine.

Health > Health Conditions and Concerns

Domainbergonie.fr

Year Founded--

Employees501 - 1000

Annual Revenue--

Bergonie Institute

Bergonie Institute (including company regionals)

bergonie.fr

See more website traffic and engagement information

Total visits to Bergonie Institute's top domains

Understand Bergonie Institute market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

bergonie.fr4.3K

See more with Sales Intelligence

Avg. visit duration in Bergonie Institute's top domains

Analyze Bergonie Institute engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

bergonie.fr00:00:30

See more with Sales Intelligence

Avg. pageviews on Bergonie Institute's top domains

See how Bergonie Institute keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

bergonie.fr1.50

See more with Sales Intelligence

Bergonie Institute top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Bergonie Institute

These are the website technologies, by industry, used by Bergonie Institute top domains

Widget (6)

Twemoji

Social (5)

Instagram

Advertising (2)

Google Adsense

Audio Video Media (2)

YouTube

More Technologies

8

See all

News & Signals from Bergonie Institute

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMendus AB partnered with Bergonie on Jul 1st '24.In July, Mendus announced a collaboration with Institut Bergonié, a leading cancer research centre based in Bordeaux, France, to study ilixadencel in soft tissue sarcomas as part of the REGOMUNE trial, a multicenter, prospective open-labeled phase 1/2 trial combining regorafenib, a tyrosine kinase inhibitor (TKI), and avelumab, an immune checkpoint inhibitor, in solid tumors.